Based on the results of this study and others (23, 26, 27), we anticipate future refinement of AGES for bupropion and other smoking cessation medications to come with advancement of basic knowledge regarding the functional effects of particular genetic variants on biological pathways implicated in smoking cessation and bupropion pharmacology, incorporation of additional genes and more complete variant coverage in relevant biological pathways (12, 67), weighting of each efficacy allele, excluding genes and variants that play little role, and determining whether additive versus dominant models are most appropriate for incorporated loci. We anticipate that this initial AGES study will help lay the groundwork for future efforts aimed to develop and refine AGES formulas for smoking cessation treatment response.
